WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011146828) CANCER TREATMENT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/146828    International Application No.:    PCT/US2011/037327
Publication Date: 24.11.2011 International Filing Date: 20.05.2011
IPC:
A61K 39/385 (2006.01), A61K 39/00 (2006.01), A61K 47/48 (2006.01), A61K 47/42 (2006.01), A61P 35/00 (2006.01)
Applicants: UNIVERSITY OF MIAMI [US/US]; 1507 Levante Avenue Max Orovitz Bldg., Suite 327 Coral Gables, FL 33124 (US) (For All Designated States Except US).
PODACK, Eckhard, R. [DE/US]; (US) (For US Only)
Inventors: PODACK, Eckhard, R.; (US)
Agent: KIM, Stanley, A.; Heat Biologics, INC. 3319 State Road 7, Suite 301 Wellington, FL 33449 (US)
Priority Data:
61/347,336 21.05.2010 US
Title (EN) CANCER TREATMENT
(FR) TRAITEMENT ANTICANCÉREUX
Abstract: front page image
(EN)A cell-based vaccine prolongs the survival of cancer patients. The vaccine includes a dose of irradiated cultured lung adenocarcinoma cells (AD 100) transfected with HLA Al and gp96-Ig (human gp96 wherein the endoplasmic reticulum retention signal, KDEL, is replaced with the Fc-portion of human IgG1 and was injected intradermally into patients suffering from advanced, relapsed, or metastatic NSCLC. Administration of the vaccine increased the mean survival time of the patients compared to that of similar patients treated with placebo. Moreover, the immune response of patients to the vaccine (antigen-induced interferon gamma production by T cells) correlated with the survival times.
(FR)L'invention concerne un vaccin cellulaire qui prolonge la survie de patients cancéreux. Le vaccin comprend une dose de cellules cultivées irradiées d'adénocarcinome pulmonaire (AD 100) transfectées par HLA Al et gp96-Ig (gp96 humain, dans lequel le signal de rétention dans le réticulum endoplasmique, KDEL, est remplacé par la partie Fc de l'IgG1 humaine et a été injecté de manière intradermique dans des patients souffrant de cancer pulmonaire non à petites cellules NSCLC avancé, récurent ou métastatique). Une administration du vaccin a augmenté la durée de survie moyenne des patients en comparaison à celle de patients similaires traités par un placebo. De plus, la réponse immunitaire des patients au vaccin, (production, par les lymphocytes T, d'interféron gamma induite par un antigène) est corrélée aux durées de survie.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)